Carboprost Tromethamine
The tromethamine salt of carboprost is administered intramuscularly to treat postpartum hemorrhage caused by uterine atony that has not responded to conventional management. As a prostaglandin F2α analog, it potently stimulates myometrial contractions. It is contraindicated in patients with active cardiac, pulmonary, renal, or hepatic disease.
Moleküler Ağırlık
489,6000 g/mol
TPSA
185,00 Ų
Etki Mekanizması
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO
InChI
InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1
Molecular Formula
C25H47NO8
HBD / HBA
8 / 9
Döndürülebilir Bağlar
15
Ağır Atomlar
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The tromethamine salt of carboprost is administered intramuscularly to treat postpartum hemorrhage caused by uterine atony that has not responded to conventional management. As a prostaglandin F2α analog, it potently stimulates myometrial contractions. It is contraindicated in patients with active cardiac, pulmonary, renal, or hepatic disease.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Carboprost Tromethamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237105. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5281074. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carboprost-tromethamine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carboprost-tromethamine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carboprost-tromethamine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carboprost-tromethamine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carboprost-tromethamine"></drugfyi-drug>